The development and progression of CML encompasses biologically and clinically distinct phases: a preclinical asymptomatic latent phase; a benign chronic phase in which myeloid differentiation is still normal, albeit deregulated; an accelerated phase, in which clinical control of leukemic cell growth is more diffi cult; and a fi nal, rapidly fatal acute phase that is characterized by an accumulation of undifferentiated blast cells (1, 2, 22) . Chronic phase CML is propagated by a population of pluripotent hematopoietic cells with many of the characteristics of normal hematopoietic stem cells (1, 2, 22) . Several studies have shown that chronic phase CML stem cell -enriched populations are less sensitive to imatinib than are the more predominant and more mature CML cells (7,23 -25) . In addition, there is growing evidence that expression of p210 BCR -ABL can induce a state of increased genomic instability (26 -28) . Therefore, we hypothesized that the slowly expanding chronic phase CML stem cell population might serve as a reservoir of cells in which mutations affecting responses to BCR-ABL -targeted therapies would inevitably accumulate, even in the absence of selection imposed by such treatments.
To test this hypothesis, we sought to determine whether mutations affecting the BCR -ABL kinase domain could be detected in the leukemic lineage-negative (lin
− (i.e., stem) cells (29, 30) from chronic phase patients who had never received BCR-ABL -targeted therapy. We also investigated whether new mutations would occur at a detectable frequency when these cells were stimulated to proliferate in vitro for up to 5 weeks. Both questions have been diffi cult to address because the lin − cells) where the majority of cells are leukemic (22) . In this study, we circumvented this problem by focusing our analyses on cryopreserved cells from patients that we had previously found by functional assays coupled with genotyping analyses to have a preponderance of leukemic cells in the stem cell compartment (29, 30) .
Materials and Methods

Cells
Heparin-treated blood and leukapheresis cells were obtained from five chronic phase CML patients who had elevated white blood cell counts (110 × 10 9 -460 × 10 9 /L) at, or up to 10 years after, the time of their initial diagnosis. None of the five patients had been treated with imatinib, and all lacked any clinical evidence of accelerated disease. Blood from normal adults and from normal adults treated with granulocyte colony-stimulating factor (G-CSF), and bone marrow from normal allogeneic transplant harvests were obtained as leftover material from the Leukemia/Bone Marrow Transplant Program of British Columbia. Bone marrow cells from normal cadaveric donors were obtained from the Northwest Tissue Center (Seattle, WA). Cord blood was obtained from normal cesarian section deliveries. In all cases, informed consent was obtained, and the procedures used were approved by the Research Ethics Board of the University of British Columbia. . The cells were then suspended in a solution of 10% dimethylsulfoxide in fetal calf serum (FCS) and cryopreserved at -135 °C until required (31) . Immediately before use, the cells were thawed and stained with antibodies to CD34 directly conjugated to fl uorescein isothiocyanate and to CD38 directly conjugated to phycoerythrin (Becton Dickinson Immunocytometry System, San Jose, CA). After staining for 30 minutes at 4 °C, the cells were washed twice in phosphate-buffered saline (PBS) containing 2% FCS (StemCell Technologies Inc) and resuspended in 2 µ g/mL propidium iodide (Sigma, − cells were collected by fl uorescence-activated cell sorting (FACS) using a FACStarPlus or FACSVantage cell sorter (Becton Dickinson) (32) .
Fluorescence In Situ Hybridization
Aliquots of approximately 2000 cells in 200 µ L of PBS containing 2% FCS were centrifuged at 400 g for 5 minutes in a Beckman Coulter Allegra 6R Centrifuge (Beckman Coulter Canada Inc, Mississauga, ON, Canada). The cell pellets were then resuspended in hypotonic potassium chloride (75 mM) and placed for 10 minutes on slides pretreated with poly-l -lysine (Sigma). A drop of 20% fixative (3 : 1 methanol/glacial acetic acid) in hypotonic potassium chloride was added, and after 3 minutes, the slides were immersed in fixative for 15 minutes and dried on wet paper towels placed on a 40 °C slide warmer. The slides were then immersed in 2× saline sodium citrate buffer at 37 °C for 1 hour and then dehydrated in an ethanol series (70%, 85%, and absolute ethanol, 2 minutes at each concentration). Fluorescence in situ hybridization (FISH) analyses were performed with a BCR -ABL dual-color translocation probe according to the manufacturer's (Vysis Inc, Downers Grove, IL)
CONTEXT AND CAVEATS
Prior knowledge
While treatment with imatinib causes remissions in the majority of patients with chronic myeloid leukemia, relapses often occur. The mechanisms by which resistance to imatinib develops are not well characterized.
Study design
Chonic myeloid leukemia stem cells from patients were isolated and genetically characterized for mutations in the oncogene (BCR -ABL) that causes the disease.
Contribution
These chronic myeloid leukemia stem cells were found to be genetically unstable, with a high frequency of mutation, leading to alterations in the BCR -ABL protein, the target of imatinib.
Implications
Resistance to imatinib may ultimately derive from mutations in a population of chronic myeloid leukemia stem cells that occur before exposure to chemotherapy. Further investigation of how mutations develop in these particular cells is needed.
Limitations
More research will be needed to translate these insights into improved therapeutics for patients.
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instructions. Interphase nuclei were evaluated under a ×63 oil immersion lens on a Zeiss Axioplan microscope with a set of 4 ′ ,6-diamidino-2-phenylindole (DAPI)/orange/green filters. Images were captured using a color capture device camera and a Genus 3.6 imaging system from Applied Imaging (San Jose, CA). FACS-sorted lin   −   CD34   +   CD38 − cells from CML patients were collected into microfuge tubes containing serum-free medium, which consisted of Iscove's medium supplemented with 10 mg/mL bovine serum albumin, 10 µ g/mL insulin, 200 µ g/mL transferrin (StemCell Technologies Inc), 40 µ g/mL low-density lipoproteins, and 10 − 4 M 2-mercaptoethanol (both from Sigma). Aliquots (of 1 mL) containing 5 × 10 4 cells were then added to each well of a 24-well plate with or without imatinib (0.1 -10 µ M, Novartis, Basel, Switzerland) and with or without the following combination of human recombinant growth factors: interleukin (IL)-3 (20 ng/mL; Novartis), IL-6 (20 ng/mL; Cangene, Mississauga, ON, Canada), G-CSF (20 ng/mL, StemCell Technologies Inc), flt3-ligand (100 ng/mL; Immunex Corp, Seattle, WA), and Steel factor (100 ng/mL, StemCell Technologies Inc). The media were replaced every week with fresh media with or without the same imatinib and growth factor supplements. At various time points, viable cell numbers were determined by hemocytometer counts of trypan blue -excluding cells.
Suspension Cultures
Progenitor Assays
Assays for quantification of colony-forming cells (CFCs) present in FACS-purified lin   −   CD34   +   CD38 − cells and their progeny generated from 3-week suspension cultures from CML patients were performed in FCS-containing methylcellulose medium (H4535, StemCell Technologies Inc) in the absence or presence of imatinib (1 -5 µ M). Erythroid, granulocyte -macrophage, and mixed-lineage colonies were scored visually using an inverted microscope and a scoring grid after 14 days of incubation as previously described (33) . Five to ten individual CFC-derived colonies from each treatment condition studied in the 3-week suspension culture experiments were analyzed cytogenetically for the presence of the Ph. Results were based in each case on an examination of at least two Giemsa-banded metaphases per individually processed CFCderived colony (34) .
Quantitative Reverse Transcription -Polymerase Chain Reaction Analyses
Total RNA was extracted from aliquots of FACS-purified CML cells and their progeny from both suspension cultures and the colonies the cultured cells formed in the methylcellulose assays using the Absolutely RNA Microprep Kit (Stratagene, La Jolla, CA) or the PicoPure RNA Isolation Kit (Arcturus, Mountain View, CA). DNase I was added during the RNA isolation step according to the manufacturer's instructions to minimize contamination with genomic DNA. RNA (0.1 -0.25 µ g) was reverse transcribed in a 20-µ L reaction volume using random hexamers as primers and SuperScript II reverse transcriptase according to the manufacturer's instructions (Invitrogen, Burlington, ON, Canada) (35) . Next, 25 µ L of 2× SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) was combined with 1 µ L of a 20 µ M solution of the specific primers, 1 -2 µ L complementary DNA (cDNA), and water to a final volume of 50 µ L. Optimal amplification of BCR -ABL and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNAs was achieved with the following primers: 5 ′ -CATTCCGCTGACCATCAATAAG-3 ′ and 5 ′ -GATGCT ACTGGCCGCTGAAG-3 ′ (BCR -ABL) and 5 ′ -CCCATCACC ATCTTCCAGGAG-3 ′ and 5 ′ -CTTCTCCATGGTGGTGAA GACG-3 ′ (GAPDH). An initial AmpErase UNG (uracil-Nglycosylate) activation step (50 °C for 2 minutes), followed by a denaturation step (95 °C for 10 minutes) and 40 cycles of amplification (95 °C for 15 seconds and 60 °C for 60 seconds) were carried out with a single fluorescence measurement per cycle. Real-time polymerase chain reaction (PCR) products were subjected to melting curve analysis to verify that target amplicons were amplified and that primer dimers were not present (36, 37) . Reactions and data analysis were performed using an Applied Biosystems 7500 Real-Time PCR system and SDS V1.4 Software (Applied Biosystems).
To compare BCR -ABL transcript levels in different cell populations, the threshold cycle (Ct) values of all the samples were fi rst normalized to the Ct value of an endogenous housekeeping gene (GAPDH) in the same sample and then this normalized value was compared to the normalized value of the reference sample (e.g., the day 0 sample) using the following formula: relative expression of BCR -ABL in the sample of interest normalized to that of the reference sample = 2 -⌬ ⌬ Ct , where ⌬ ⌬ Ct is ⌬ Ct, sample -⌬ Ct, reference. ⌬ Ct, sample is the Ct value for any sample normalized to GAPDH, and ⌬ Ct, reference is the Ct value for the calibrator (e.g., day 0 sample) also normalized to the Ct value for GAPDH. The effi ciency of amplifi cation of both GAPDH and BCR -ABL sequences was confi rmed to be close to 100% from the observed linear relationship obtained between the value for ⌬ Ct and the template cDNA dilution. Samples from three patients were used to compare the transcript levels of BCR -ABL from freshly isolated lin
− cells, from progeny cells harvested 3 weeks later from cultures, and from individual CFC-derived colonies grown in the presence and absence of imatinib. The BCR -ABL transcript levels in suspension-cultured cells were determined from three independent experiments each combining samples from the same three patients. For determining transcript levels in CFC-derived colonies, colonies grown from a total of eight nonmutant and 12 mutant CFCs pooled from all three patients were used.
Mutation Analysis
Mutations in sequences encoding the BCR -ABL kinase were identified in CML cells using a previously described method (38) with some modifications. Total RNA was extracted from FACS-purified subsets of normal and CML cells and their progeny gen erated in suspension culture or in CFC assays using the Absolutely RNA Nanoprep Kit (Stratagene) or the PicoPure RNA Isolation Kit (Arcturus). The sequence corresponding to the BCR -ABL kinase domain was amplified using a two-step reverse transcription (RT) -PCR method (38) . The cDNA thus obtained was then amplified with the Platinum Taq DNA polymerase High Fidelity (Invitrogen). In the first step of the PCR, a 1.3-kilobase (kb) BCR -ABL fusion fragment was amplified using the primer BCR-ATPB1 (5 ′ -GAAGCTTCTCCCTGACATCCGTG-3 ′ , nucleotide position 3205 -3227, GenBank accession number NM _004327) and ABL-ATPB2 (5 ′ -GCCAGGCTCTCGGGTGCAGTCC-3 ′ , nucleotide position 1578 -1600, and GenBank accession number M 14752) as primers and then purified by agarose gel electrophoresis. A second PCR was then used to amplify the ABL kinase domain using ABL-ATPB1 (5 ′ -GCGCAACAAGCCCACTGTCTATGG-3 ′ ) and ABL-ATPB2 as primers. The 0.6-kb product was purified and cloned into the pCR2.1-TOPO vector (Invitrogen). In control experiments, BCR -ABL PCR products were not obtained from extracts of normal bone marrow cells or other leukemic cell lines (Hut 78 and Hut 102 from American Type Tissue Collection, Manassas, VA) that do not contain a BCR -ABL fusion gene. At least five bacterial colonies obtained by transformation with the cDNA prepared from each CFC-derived colony or 10 -20 bacterial colonies from the cDNA prepared from fresh or cultured cells were inoculated into media. Plasmid DNA was then isolated from the cultured bacterial cells by standard methods and sequenced using a 3730XL DNA Analyzer System from Applied Biosystems. A mutation was considered to be present only if it was detected in both strands in two or more independent bacterial clones transformed with the cDNA from the suspension culture cells or CFC-derived colonies. Sequence analysis of a 0.7-kb fragment of BCR -ABL immediately 5 ′ to the kinase domain was performed by amplifying the 1.3-kb BCR -ABL fusion fragment described above using BCR-ATPB1 and ABL-ATPB3 (5 ′ -CCA-TAGACAGTGGGCTTGTTGCGC-3 ′ ) and cloning it into the pCR2.1-TOPO vector. A 0.6-kb fragment derived from the wildtype ABL kinase domain in extracts obtained from normal bone marrow cells was amplified using the ABL-ATPB1 and ABL-ATPB2 primers, and then cloned and sequenced.
Allele-Specific Real-Time Polymerase Chain
Reaction Analysis RNA extraction and cDNA synthesis for allele-specific real-time PCR analyses were carried out as described above. PCR conditions for the allele-specific PCR amplification of each of the 16 previously described BCR -ABL kinase domain mutations studied were first individually optimized for maximal sensitivity and specificity using mixtures of wild-type and mutant plasmids in varying ratios from 1 : 10 5 to 1 : 1. Primer sequences, PCR conditions, and the sensitivity of this assay are given in Supplementary Table 1 (available online). Optimal PCR conditions for the amplification of each kinase domain mutation were further verified in various sources of normal bone marrow, cord blood cells, and mobilized peripheral blood samples. The specificity with which each separate mutation was detected in CML cells by PCR amplification was determined both by melting curve analysis (to confirm true target amplicons and the absence of primer -dimer artifacts or contaminants) ( Supplementary Fig. 1 , available online) and by electrophoresis to confirm the presence of a PCR fragment of the predicted length on a 1.5% ethidium bromide -stained agarose gel, as shown in Fig. 1 , A . + CD38 − cells isolated from CML patients and K562 cells, a cell line derived from a CML patient in blast crisis) were lysed in phosphorylation solubilization buffer (50 mM Hepes buffer, 100 mM NaF, 10 nM sodium pyrophosphate, 2 mM Na 3 VO 4 , and 4 mM EDTA) containing 0.5% Nonidet P-40 and protein inhibitor cocktail (Sigma) as previously described (35) . Proteins in cell lysates were separated by polyacrylamide gel electrophoresis (NuPage BisTris 4% -12% gel, Invitrogen) followed by electroblotting on a polyvinyl difluoride membrane (Millipore, Billerica, MA). Each membrane was then blocked with 5% skim milk, incubated with primary antibody, washed, and then incubated with a horseradish peroxidase -conjugated secondary antibody (Jackson Immunoresearch, West Grove, PA). Antibody binding was detected by incubating the membrane with Western lighting chemiluminescence reagent (PerkinElmer Life and Analytical Sciences, Inc; Boston, MA) and exposing it to Kodak X-Omat film (Eastman Kodak, Rochester, NY). Primary antibodies used in this study included a monoclonal anti-abl antibody (8E9, 1 : 500 dilution, Pharmingen, Mississauga, ON, Canada), an anti-phosphotyrosine antibody (4G10, 1 : 2000 dilution, Upstate Biotechnology, Lake Placid, NY), and antiphospho-CrkL and anti-CrkL antibodies (1 : 500 dilution for each, Cell Signaling Technology, Beverly, MA). In some experiments, membranes were stripped with strippingbuffer (2.5 mM Tris-Cl [pH 6.8], 2% sodium dodecyl sulfate, 100 mM 2-mercaptoethanol) at 50 °C for 30 minutes before being reblocked, washed, and reprobed. * PCR-amplified cDNAs from BCR -ABL transcripts present in RNA extracts of the cells indicated were cloned and amplified in bacteria, and the cloned sequences were individually sequenced as described in the Methods. CML = chronic myelogenous leukemia; cDNA = complementary DNA; PCR = polymerase chain reaction.
Immunoblot Analyses
The intensity of chemiluminesence was measured using a STORM 860 phosphoimager and ImageQuant software from Molecular Dynamics (Sunnyvale, CA, USA). The extent of phosphorylation of p210 BCR -ABL and CrkL was then determined by comparing the chemiluminescence derived from the binding of antibodies specific for Table 1 ).
phosphotyrosine or phospho-CrkL to the chemoluminescence derived from the binding of antibodies raised to p210 BCR -ABL or CrkL.
Statistical Analysis
Results are shown as the mean ± 95% confidence intervals of values obtained in independent experiments. Differences between groups were assessed using the two-sided Student's t test.
Results
Accumulation of BCR -ABL Mutations in Chronic Myeloid Leukemia Stem Cells In Vivo
To obtain an enriched population of CML stem cells, we used FACS to isolate the lin -CD34 + CD38 − subset of cells from three patients' samples in which these cells had been previously found to be 55% -100% Ph-positive (Ph + ) by FISH (data not shown). We then generated BCR -ABL cDNA by reverse transcription of RNA extracted from these cells and subcloned the PCR-amplified kinase domain sequence into a plasmid vector. Sequencing of the cloned fragments revealed that 33%, 20%, and 30% of the cloned cDNAs (nine or 10 from each patient) from patients 1, 2, and 3, respectively, contained mutations ( Table 1 ). In contrast, we did not detect any kinase domain mutation among 30 cloned ABL cDNAs generated from extracts of lin
− cells that were isolated from three different normal adult human bone marrow samples.
We also used a highly sensitive allele-specifi c real-time PCR method to look for specifi c point mutations in BCR -ABL cDNAs from two of the same three CML patients' samples studied by sequencing. Sixteen point mutations (Supplementary Table 1 − cells) from the same patients. We identifi ed fi ve different mutant sequences in the leukemic stem cells from these patients ( Fig. 1, B ) , including two (one encoding F359L in patient 1 and one encoding K400E in patient 3) that had also been found by direct sequencing. None of the mutations surveyed were detected in the more mature (lin − CD34 + ) cells (data not shown), but it is possible that the lower levels of BCR -ABL transcripts present in these cells (7, 39) would have reduced the sensitivity of the allele-specifi c real-time PCR method for detection of mutations.
To investigate the specifi city of the allele-specifi c real-time PCR methodology for detecting pre-existing mutations in cDNAs prepared from leukemic cells (as opposed to artifactual changes in transcript sequence acquired during the previous PCR steps), extracts from nine different samples of normal control cells were subjected to the same analysis as had been applied to the leukemic cells. Six of these control samples were lin − CD34
+ cells from various sources (two from normal adult bone marrow samples, two from large pools of cord blood cells, and two from G-CSF -mobilized peripheral blood progenitor cells harvested from normal adults). The other three were normal granulocytes isolated by density centrifugation of normal human blood. None of the 16 BCR -ABL kinase domain mutations surveyed were detected in any of the control samples, as evidenced by allele-specifi c real-time PCR and the absence of amplifi ed fragments in agarose gels stained with ethidium bromide. 
Generation of Imatinib-Resistant Colony-Forming Cells From Chronic Myeloid Leukemia Stem Cells Incubated In Vitro
We then sought to determine whether additional mutations in BCR -ABL accumulated in the progeny of chronic phase CML stem cells stimulated to proliferate in vitro. Accordingly, we isolated the lin
− fraction of cells by FACS from the three patients with predominantly leukemic cells in this compartment as well as from two other patients and then used these cells to establish serum-free suspension cultures. The cultures contained either no imatinib (controls) or from 0.1 to 10 µ M imatinib. Half of the cultures contained a supportive combination of growth factors (20 ng/ mL IL-3, 20 ng/mL IL-6, 20 ng/mL G-CSF, 100 ng/mL flt3-ligand, and 100 ng/mL Steel factor) and the other half contained no added growth factors. In both cases, the medium was replaced at weekly intervals. Time course studies showed that the yield of viable cells decreased as a function of imatinib dose, with the most pronounced decrease seen in cultures to which no growth factors were added ( Fig. 2, A ) .
The lin − CD34 + CD38 − cells used to establish 3-week suspension cultures as well as the cells harvested from the 3-week suspension cultures were also assayed for CFCs in methylcellulose cultures. Burst-forming units-erythroid (BFU-Es), colonyforming units-granulocyte -macrophage (CFU-GMs), and colony-forming units-granulocyte -erythrocyte -monocytemegakaryocyte (CFU-GEMMs) were detectable at the same numerical frequencies in both populations ( Fig. 2, B cells had differentiated into morphologically recognizable granulocytes and macrophages, as expected from previous studies (32, 40) .
To determine whether 3 weeks in culture selected for the outgrowth of an initially minor residual normal stem cell population, we used FISH and metaphase karyotyping to genotype the colonies generated in methylcellulose from harvests of the 3-week suspension cultures established from two of the CML patients (patients 1 and 2). A total of 84 metaphases were analyzed from colonies generated in the presence or absence of growth factors and imatinib, and more than 300 cells from the 3-week suspension cultures maintained under the same treatment conditions were analyzed by FISH. The results of these analyses confi rmed that essentially all the cells in the 3-week cultures established from patient 1 were leukemic (i.e., 100% BCR/ABL We also compared the imatinib sensitivity of the CFCs in the freshly isolated lin − CD34 + CD38 − cells with the imatinib sensitivity of the leukemic CFCs obtained from the 3-week suspension cultures established with the same lin − CD34 + CD38 − cells by assessing the ability of the cells from both sources to form colonies in semisolid medium containing 0, 1, or 5 µ M imatinib. The results of these measurements show that the CFCs harvested from the 3-week cultures ( Fig. 2, C ) were substantially less sensitive to imatinib than those present in the original lin − CD34 + CD38 − populations ( Fig. 2, B ) .
Using immunoblotting approaches, we determined the levels of p210 BCR -ABL , its kinase activity (as refl ected in the extent of Crk-L phosphorylation), and the extent to which it was tyrosine phosphorylated in cells that had been grown from lin
− cells in the presence of 10 µ M imatinib. We then compared these values to those obtained for cells grown from the same input cells in the absence of imatinib. Blots prepared from electrophoresed extracts of the cells were fi rst probed with an antibody to phosphotyrosine and one specifi c for the phosphorylated form of CrkL. The blots were then stripped and reprobed with antibodies that recognized p210 BCR -ABL or CrkL, irrespective of their phosphorylation status. The chemiluminescence intensities of the bands corresponding to phosphorylated and total protein were then compared. The cells grown in the 3-week suspension cultures that contained 10 µ M imatinib showed no detectable decrease in the extent of phosphorylation of either p210 BCR -ABL or CrkL ( P = .95 and .88, respectively) by comparison to the same cells cultured in the absence of imatinib ( Fig. 3, A ) . This fi nding suggested that 3 weeks growth in vitro under these conditions had selected for cells that had acquired some genetic form of imatinib resistance. We did not detect any evidence of BCR -ABL gene amplifi cation in these cells by FISH analysis (after analyzing more than 300 cells, data not shown). These fi ndings prompted us to determine whether the time in culture had selected for pre-existing BCR -ABL mutations and/or whether new BCR -ABL mutations had been acquired.
Detection of New BCR -ABL Mutations in Cells Derived From Chronic Myeloid Leukemia Stem Cells Incubated In Vitro
The first indication that new mutations might be present in the progeny of cultured CML stem cells was provided by cytogenetic analysis of Giemsa-banded metaphases obtained from individually processed CFC-derived colonies produced from the 3-week suspension culture cells (a total of 84 metaphases). These studies identified one colony in which four of four metaphases analyzed contained a previously undetected 17p + abnormality ( Fig. 3, B ) . To look for mutations in the BCR -ABL gene of the cultured cells, we sequenced 235 subcloned PCR-amplified cDNA fragments obtained both from extracts of the 3-week suspension cells (58 clones, Table 1 ) from three patients and the rest from 37 individual colonies generated from these cells (listed in Table 2 ). By sequencing, we identified 65 point mutations in the sequence encoding the BCR -ABL kinase domain that had not been detected in the original lin
− cells from which the cultures had been established ( Table 3 , Fig. 4, A and B ) .
To determine whether the BCR -ABL kinase domain is particularly prone to mutation in CML cells, we used the same cDNA-based sequencing approach to search for mutations at two additional locations in the BCR -ABL gene in cells from six colonies generated from the same 3-week cultures that had already been analyzed for kinase domain mutations. Both locations were 5 ′ of the kinase domain; one extended into the BCR sequence. From sequencing 23 PCR-amplifi ed cDNA fragments from the three patient samples analyzed, 21 mutations were identifi ed ( Table 4 ) . These results show that these additional regions were also highly susceptible to mutations. In contrast, using specifi c primers to amplify ABL cDNAs from similarly cultured lin − CD34 + CD38 − cells derived from two normal adult human bone marrow samples and sequencing a total of 17 cDNA fragments, we detected only four mutations (23%, Table 4 ).
Because the studies of transcripts from the leukemic CFCderived colonies were performed on single colonies, it was possible to determine whether the mutations were already present in the individual CFCs from which the colonies arose (preexisting mutations would be expected to be present in all transcripts from a single colony, whereas mutations acquired de novo during colony growth would lead to a mixed pattern of wild-type and mutant transcripts). Colonies that had been grown from single cells that were harvested from the 3-week suspension cultures (containing either 0 or 5 µ M imatinib) and then plated in methylcellulose assays were picked, RNA extracts were prepared, and cDNA fragments containing the BCR -ABL kinase domain were then amplifi ed by PCR. After purifi cation, these cDNAs were cloned into a (Table continues) bacterial vector to generate transformants. Several transformants were isolated for each extract investigated and DNA extracts obtained from each for sequencing ( Table 2 ) . Most of the 37 colonies examined were found to contain both wild-type and mutant transcripts, and 18 contained more than a single type of mutant transcript. A lower frequency of BCR -ABL kinase domain mutations was observed in the colonies grown in the absence of imatinib than its presence in all three patient samples studied (patient 1: 23% versus 40%, patient 2: 27% versus 50%, and patient 3: 46% versus 68%; Table 2 ). These results demonstrate that BCR -ABL kinase domain mutations arose at a high rate during the 2 weeks of in vitro colony growth. Thus, the imatinib-resistant phenotype displayed in these CFC assays was not due solely to the acquisition during the preceding 3 weeks of culture of BCR -ABL kinase domain mutations.
To determine whether imatinib resistance of the CFCs obtained from the 3-week cultures was due in part to increased BCR -ABL expression, we used real-time RT -PCR to measure the levels of BCR -ABL transcripts in the cells of individual colonies produced in the methylcellulose media. The results showed that the cells from colonies containing some or exclusively mutant BCR -ABL transcripts expressed BCR -ABL at 30-fold higher levels than cells from colonies in which only wild-type transcripts were present ( Fig. 3, C ) . Colony growth in the presence of imatinib did not affect the level of BCR -ABL transcripts because mutant CFCs obtained from all three patient samples studied in either the presence or absence of imatinib contained similar levels of BCR -ABL transcripts. This observation suggests that the acquisition of BCR -ABL kinase domain mutations may be associated with a diminished ability to reduce BCR -ABL expression. The overall levels of BCR -ABL transcripts in the cultured cells as compared with the starting population were also reduced ( Fig. 3, C ) , as occurs when CML stem cells differentiate in vivo (7, 39) .
BCR -ABL mutations in primitive cells
TAC-C AC Y353H Y353G/H AAA-G AA/ C AA K357E/Q TTC-C TC/T C C F359L/S F359A/I/V F359C ATC-A C C I360T I360F CAC-C G C H361R AAC-A G C N368S CAC-C G C H375R GTG-G C G V377A TTT-T C T F382S F382L ATG-A C G/ G TG M388T/V M388I ACA-G CA T389A T389A GAC-G G C D391G ACC-G CC T392A TAC-T G C Y393C AAG-G AG/A G G K400E/R
Discussion
In this study, we found that the BCR -ABL fusion gene in CML stem cells is highly unstable as indicated by an unusual rate of ac cumulation of mutations in this compartment in vivo and in their progeny generated in vitro, even in the absence of imatinib exposure. This finding is consistent with the clinical observation that many chronic phase CML patients can achieve a complete cytogenetic remission (as evidenced by the absence of the BCR -ABL translocation [t 9;22] in 20 bone marrow metaphases), but complete molecular remissions (as evidenced by a reduction of BCR -ABL transcripts to levels that are undetectable by real-time RT -PCR) are rare (18, 41, 42) , and resurgence of imatinib-resistant leukemic cells remains a clinical concern. The high mutation rate in the BCR -ABL fusion gene is also consistent with recent laboratory studies that have suggested that the most primitive and/or quiescent fraction of chronic phase CML cells are relatively insensitive to either imatinib or more potent BCR-ABL -targeted agents like dasatinib at doses that kill the more mature leukemic cells (23, 43) . These studies have focused attention on the importance of these unresponsive primitive/quiescent cells in the inability of some CML patients to achieve durable responses to new therapies. It has been reported that the most common mechanism of acquired resistance to imatinib in CML patients involves either an amplifi cation of the BCR -ABL gene or the appearance of point mutations in the kinase domain (15, 38) . However, another clinical study has concluded that BCR -ABL gene amplifi cation is probably a less frequent mechanism of clinical resistance to imatinib than acquisition of mutations that affect imatinib binding (16) . None of the patients studied here exhibited evidence of BCR -ABL gene amplifi cation, as indicated by FISH analysis of their primitive cells, nor was amplifi cation of the BCR -ABL gene detected in cells cultured with or without imatinib. BCR -ABL mutations that affect imatinib binding have occasionally been detected in patients before the initiation of imatinib therapy (16, 17) and have been hypothesized to result from an inherent genetic instability in BCR-ABL -transformed cells (38, 44) . However, their presence in the lin − CD34 + CD38 − cells from imatinib-naive chronic phase CML patients has not been documented previously. Here, we have shown that numerous mutations in the sequence encoding the kinase domain of BCR -ABL were present at detectable frequencies in the most primitive leukemic cells of all three chronic phase CML samples that were examined, even though the samples were from patients who had never been treated with imatinib. More recent studies with samples from an additional 12 chronic phase CML patients have corroborated these results (Jiang X, Forrest D, Smith C, Eaves A, Eaves C: unpublished data). These data clearly support the idea that kinase domain mutants arise spontaneously and at a clinically relevant frequency in chronic phase CML stem cells expanding in vivo.
Another important contribution of this study was the observation of the high incidence and variety of mutations identifi ed in cultured CML cells (either with or without imatinib). Overall, point mutations affecting 77 different nucleotides within the kinase domain of BCR -ABL were identifi ed by sequencing transcripts obtained from either fresh CML cells or their progeny. Most were point mutations, and up to three different substitutions were identifi ed at some sites in different samples. The majority were A → G (46%), T → C (27%), and C → T (5%) transitions previously associated with imatinib resistance (28, 42) . In some instances, more than a single mutation could be found in the same cloned transcript ( Fig. 4 and Tables 3 and 4 ) . Of the mutations identifi ed, 30 have been previously reported. Ten of the substitutions (N231Y, D241A, G250R, D276G, T277A, V289A, T315I/A, M343V, F359L/S, and F382S) have been associated with imatinib resistance in patients and two (G250R and T315I) with imatinib resistance in vitro as well (15,18,38,45 -49) . T315I has recently been reported to confer resistance to dasatinib and/or nilotinib, two more recently developed inhibitors of the BCR -ABL kinase (9 -11) . Another fi ve substitutions (D276G, V304A, E352K, Y353H, and T389A) have been identifi ed in CD34 + cells from imatinib-treated CML patients in complete cytogenetic remission (48) . To the best of our knowledge, the other 47 point mutations have not been previously described. In addition, we discovered three novel frameshift mutations and three mutations that result in premature termination codons, leading to truncated proteins ( Fig. 4, A and Table 3 ). Mutations were also found outside the kinase domain of BCR -ABL, consistent with the concept that CML cells have heightened genetic instability in vitro (28) . Taken together, these fi ndings strongly implicate BCR -ABL instability in CML stem cells in the development of imatinib resistance.
Analyses of BCR -ABL transcripts present in individual colonies generated in CFC assays of the 3-week suspension cultures revealed cases in which an individual colony of cells sometimes contained a mixture of wild-type transcripts and one, or two, or even three different mutant transcripts. These data indicate that new mutants arose during the process of colony formation; i.e., within 8 -10 cell divisions. This rapid generation of BCR -ABL mutants in primary CML cells in vitro is the same type of genome instability that was recently demonstrated in murine BaF3 cells (50) and adult bone marrow cells (51) transduced with a BCR -ABL vector. Future experiments will be required to determine whether the genetic instability manifested by cultured CML cells is due to a heightened sensitivity to reactive oxygen species produced in cultures maintained in 20% oxygen, as has been recently suggested (28) .
Our study clearly demonstrates that CML stem cells are an important target population for the development of the BCR -ABL mutations associated with the development of imatinib resistance in vivo and in vitro. Nevertheless, some potential limitations of this study should be considered. First, the studies of CML stem cell properties presented here were largely confi ned to a small number of chronic phase CML patients' samples whose stem cell compartment contained predominantly leukemic cells. Caution needs to be exercised in extrapolating from these fi ndings to more typical chronic phase CML patients in whom the leukemic stem cells are much less numerous. A second limitation of this study is the lack of mecha nistic data to explain the altered genomic stability seen due to the very small numbers of leukemic stem cells that can be accessed, even from patients' in whom the majority of stem cells are leukemic.
Taken together, our fi ndings support the concept that chronic phase CML stem cells exhibit heightened genomic instability that allows these cells to diversify genetically. As a result, with slow but continued expansion of the chronic phase stem cell compartment over time in vivo, subclones of mutant stem cells with a variety of altered features would be expected to appear. The subclones could have mutations that confer a growth disadvantage leading to their extinction as well as mutations that would be growth neutral but confer resistance to BCR-ABL -targeted therapies and thus provide a selective growth advantage upon the administration of such therapies. Although this study was not designed to identify mutations that would contribute to disease progression, our re sults suggest that these would also be found. These considerations highlight the importance of gaining further understanding of the control of DNA replication and repair in the leukemic stem cells from patients with chronic phase CML in future efforts to devise therapies with curative potential.
